Skip to main content

Table 3 Clinical outcomes between high-intensity and low-moderate-intensity statin in three different glycemic statuses at 2 years

From: Comparative effect of statin intensity between prediabetes and type 2 diabetes mellitus after implanting newer-generation drug-eluting stents in Korean acute myocardial infarction patients: a retrospective observational study

Outcomes High-intensity
(n = 806)
Low-moderate-intensity (n = 1815) Log-rank Unadjusted Adjusteda
HR (95% CI) p value HR (95% CI) p value
Normoglycemia Group A1 Group B1      
MACE 23 (3.4) 104 (6.4) 0.004 1.924 (1.225–3.022) 0.005 1.903 (1.203–3.010) 0.006
All-cause death 8 (1.2) 28 (1.7) 0.311 1.497 (0.682–3.286) 0.314 1.342 (0.604–2.982) 0.471
Cardiac death 5 (0.6) 20 (1.1) 0.265 1.733 (0.650–4.619) 0.271 1.628 (0.602–4.402) 0.336
Re-MI 9 (1.4) 27 (1.7) 0.555 1.254 (0.590–2.668) 0.556 1.238 (0.570–2.690) 0.589
Any revascularization 8 (1.1) 60 (3.9) 0.001 3.146 (1.504–6.579) 0.002 3.248 (1.539–6.854) 0.002
Outcomes High-intensity
(n = 935)
Low-moderate-intensity (n = 2145) Log-rank Unadjusted Adjusteda
HR (95% CI) p value HR (95% CI) p value
Prediabetes Group A2 Group B2      
MACE 61 (7.3) 139 (6.9) 0.656 1.071 (0.792–1.447) 0.656 1.112 (0.818–1.510) 0.499
All-cause death 21 (2.5) 48 (2.4) 0.846 1.052 (0.630–1.757) 0.846 1.103 (0.653–1.862) 0.715
Cardiac death 15 (1.7) 34 (1.7) 0.885 1.046 (0.569–1.920) 0.886 1.014 (0.542–1.897) 0.966
Re-MI 16 (1.9) 35 (1.7) 0.769 1.092 (0.605–1.974) 0.769 1.166 (0.639–2.130) 0.617
Any revascularization 28 (3.5) 60 (3.1) 0.520 1.158 (0.740–1.814) 0.521 1.152 (0.730–1.819) 0.543
Outcomes High-intensity
(n = 1243)
Low-moderate-intensity (n = 2949) Log-rank Unadjusted Adjusteda
HR (95% CI) p value HR (95% CI) p value
T2DM Group A3 Group B3      
MACE 96 (9.0) 254 (9.2) 0.654 1.055 (0.834–1.335) 0.654 1.010 (0.796–1.282) 0.934
All-cause death 41 (3.8) 99 (3.6) 0.876 1.029 (0.715–1.482) 0.876 1.139 (0.787–1.650) 0.491
Cardiac death 28 (2.6) 63 (2.2) 0.690 1.095 (0.701–1.709) 0.690 1.238 (0.788–1.945) 0.354
Re-MI 29 (3.0) 69 (2.6) 0.748 1.074 (0.696–1.657) 0.748 1.108 (0.713–1.720) 0.649
Any revascularization 42 (4.0) 102 (3.8) 0.843 1.037 (0.724–1.486) 0.843 1.059 (0.736–1.526) 0.756
Outcomes High-intensity
(n = 2984)
Low-moderate-intensity (n = 6909) Log-rank Unadjusted Adjusteda
HR (95% CI) p value HR (95% CI) p value
Total Group A1 + A2 + A3 Group
B1 + B2 + B3
     
MACE 180 (7.0) 497 (7.8) 0.164 1.129 (0.952–1.339) 0.164 1.070 (0.900–1.273) 0.444
All-cause death 70 (2.7) 175 (2.7) 0.824 1.032 (0.782–1.362) 0.825 1.083 (0.816–1.436) 0.581
Cardiac death 48 (1.8) 117 (1.8) 0.920 1.017 (0.727–1.424) 0.920 1.099 (0.781–1.546) 0.590
Re-MI 54 (2.2) 131 (2.1) 0.922 1.016 (0.740–1.395) 0.922 1.066 (0.771–1.473) 0.700
Any revascularization 78 (3.1) 222 (3.6) 0.285 1.151 (0.889–1.490) 0.286 1.131 (0.870–1.470) 0.358
  1. HR: Hazard ratio; CI: confidence interval; T2DM: type 2 diabetes mellitus; MACE: major adverse cardiac events; Re-MI: recurrent myocardial infarction; LVEF: left ventricular ejection fraction; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; NT-ProBNP: N-terminal pro-brain natriuretic peptide; LDL: low-density lipoprotein; ACEI: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; IVUS: intravascular ultrasound
  2. aAdjusted by age, male, LVEF, BMI, SBP, DBP, cardiogenic shock, hypertension, current smoker, NT-ProBNP, total cholesterol, triglyceride, LDL-cholesterol, ticagrelor, ACEI, ARB, atorvastatin, rosuvastatin, simvastatin, IVUS, and stent diameter